Ultimately, by inducing cardioprotective HSP expression, the HALT&REVERSE Consortium wants to halt or even reverse the structure of cardiomyocytes and therefore the electropathology in patients with AF (Fig. 4c). Here, HSP90B2P is linked to atrial fibrillation.